GSK and Novartis report earnings
Amgen adopts a two-price technique for Humira’s first biosimilar, Amjevita
Anticipated legislative hurdles for biopharma in 2023
Bayer below strain from buyers to hurry up CEO change
Amgen adopts a two-price technique for Humira’s first biosimilar, Amjevita
Anticipated legislative hurdles for biopharma in 2023
Bayer below strain from buyers to hurry up CEO change
*Please scroll down for the most recent information*
Stay up to date with the latest coronavirus news related to the pharmaceutical industry on our new page
As we speak’s hottest searches:
#February #GSK #Novartis #report #earnings